The immune system produces antibodies in response to pathogen invasion. Antigens are the collective term for the invasive bacteria, viruses, or other foreign molecules. Antibodies are proteins, or polypeptides which have specific antigen recognition sites. It is possible to have antibodies made using custom antibody production when an antibody is required against a particular antigen but it is not offered by a supplier. These antibodies can be either polyclonal or monoclonal, depending on how they are produced and harvested. Polyclonal antibodies are capable of recognizing multiple sites on an antigen. They are derived from different B-cell lineages. Monoclonal antibodies recognize only one epitope or site on an antigen, and are derived from a single B-cell line.
Global custom antibody service market is estimated to be valued at US$ 444.85 Million in 2022 and expected to reach US$ 930.46 million by 2030, witnessing a CAGR of 9.7 % over the forecast period (2022-2030).
Figure 1. Global Custom Antibody Service Market Share (%), By Region, 2022
Market players are indulged in launching customized services for the development of custom antibodies that are used for research purposes, and this is expected to create lucrative growth opportunities in the custom antibody service market
The increase in organic strategies like new customized service launch is expected to drive the growth the market. For instance, in November 2020, AMSBIO, a leading provider of quality life science research reagents and services, announced the launch of development services for rabbit and mouse recombinant monoclonal antibodies. The DimAb development platform, a technology revolution for monoclonal antibody development, which differs from traditional hybridoma fusion methods, is the foundation for the creation of recombinant monoclonal antibodies. It can extract IgG genes from B cells of animals that have received an immunization. These antibodies aid in the creation and marketability of pharmaceuticals.
|Base Year:||2021||Market Size in 2022:||US$ 444.85 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||9.7%||2030 Value Projection:||US$ 930.46 Mn|
Thermo Fisher Scientific, Inc., Genscript, Abcam plc., Cell Signaling Technology, Inc, Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Inc., BioLegend, Inc., ROCKLAND IMMUNOCHEMICALS, INC., ProMab, Innovagen AB, ProteoGenix, Bio-Techne., Creative Diagnostics., Sino Biological, Inc., RayBiotech Life, Inc., Abbiotec, Inc., ProSci Incorporated, Capralogics, Inc., and Boster Biological Technology
|Restraints & Challenges:||
Figure 2. Global Custom Antibody Service Market Share (%) Analysis, By Product Type, 2022
Advantages of using antibodies for various applications is projected to propel the market growth over the forecast period.
Advantages of antibodies is expected to increase their use for various applications such as research and development, production of therapeutics, etc.
According to the National Center for Biotechnology Information (NCBI): 2020, monoclonal antibodies and polyclonal antibodies are widely used in gold standard techniques such as ELISA, western blotting, flow cytometry, and other affinity based assays or isolation techniques. For ELISA, a monoclonal antibody helps detect a specific antigen of interest. Monoclonal antibodies can also help detect specific cells in flow cytometry. They are also useful for protein purification. Monoclonal antibody can further be used to bind a protein which can then be isolated from its solution.
Global Custom Antibody Service Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Supply chain and manufacturing activities have been disrupted globally, due to lockdowns implemented by governments of countries, restricted movement, and other COVID-19 safety precautions.
Identifying individuals infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a focal point throughout the coronavirus disease (COVID-19) pandemic. This has thus created a public health need for COVID-19 testing that is timely, reliable, and widely available.
Market players and academic or research institutes are engaged in research and development activities for treatment of COVID-19 and due to this there has been increase in custom antibody services for COVID-19. This is expected to positively impact growth of the global custom antibody service market during the COVID-19 pandemic.
Global Custom Antibody Service Market: Restraint
Challenges involved in the production of customized antibodies is the major factor hampering the growth of the custom antibody services market. Some challenges includes:
Antibodies are produced by the immune system in response to invading pathogens. The invading bacteria, virus, or other foreign molecules are collectively called as antigens. Antibodies are proteins, or polypeptides which have specific antigen recognition sites. Antibodies are formed by B-cells of the immune system. When an antibody is needed against a specific antigen, but it isn’t available from a supplier, it is possible to have antibodies made via custom antibody production. These antibodies are of two types depending on how they are generated and harvested: polyclonal or monoclonal. Polyclonal antibodies are capable of recognizing multiple sites on an antigen. They are derived from different B cell lineages. Monoclonal antibodies recognize only one epitope or site on an antigen, and are derived from a single B-cell line. There are six steps to polyclonal antibody production:
Thus, key market player provide services in all or some of these above mentioned steps.
Increasing launches of new customized antibody services by key market players and advantages of using antibodies for various applications is expected to provide lucrative growth to Global Custom Antibody Service Market for the forecast period. In addition, increase in the funding by various organizations in R&D is expected to drive the growth of global custom antibody service market over the forecast period. For instance, according to an article published by R&D world on April 20, 2022, the U.S. industrial organizations are expected to collectively invest US$ 447 billion in R&D of health care. Moreover, the U.S. federal government is expected to invest US$ 181.4 billion in R&D of health care in 2022.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.